Pharma Industry News
Printable Version   Email to a friend

Senate Finance Chairman Baucus Comments on President’s FY2009 Budget

Baucus criticizes “lack of candor” about costs, says Congress will not slash Medicare for seniors

WASHINGTON, Feb. 4, 2008 – Senate Finance Committee Chairman Max Baucus (D-Mont.) commented today on President Bush’s $3.1 trillion FY2009 budget, released just this morning. The Senate Finance Committee has jurisdiction over U.S. tax policy, Medicare, Medicaid, the Children’s Health Insurance Program, Social Security, and trade, and also recently approved an economic stimulus package for consideration by the full Senate. Baucus said today that a lack of candor  about costs for future tax policy and the wars in Iraq and Afghanistan, as well as deep and unacceptable cuts to Medicare and Medicaid, are cause for concern.

“This is a pretty disappointing document, both in terms of its candor about what things really cost, and in terms of its feasibility for future years. The cost of the stimulus package that the country so badly needs is included and used to explain away the deficit, but apparently they used invisible ink on the larger costs of fixing the alternative minimum tax in future years and for funding the wars in Iraq and Afghanistan. It’s also clear from this year’s funds for the Children’s Health Insurance Program that the White House was lowballing Congress last year on the amount needed to take care of our kids,” said Baucus.

“This administration ought to know that five years’ worth of Medicare and Medicaid cuts totaling $200 billion are dead on arrival with me and with most of the Congress. They should certainly know that it’s useless to trot out their failed proposal to privatize Social Security again. Americans expect us to keep their interests at heart, and to do so with honesty and integrity. The President’s budget is a reflection of cloaked policies and irresponsible cuts to vital programs. I expect that Finance Committee members will have many questions for Secretary Paulson and Secretary Leavitt this week about how this document fails to dovetail with reality.”

Chairman Baucus and the Senate Finance Committee will host two hearings this week in response to the President’s budget proposal on Wednesday and Thursday with Secretaries Paulson and Leavitt of the Treasury and of the Department of Health and Human Services, respectively. Both hearings begin at 10:00 a.m. in Dirksen Senate Office Building 215.
# # #

Contact:
Dan Virkstis
February 4, 2008
(202) 224-4515

Latest Pharma Industry News...

Pharma Industry News Archive

2008: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Jan | Apr | May | Jun | Aug | Sep | Oct | Nov | Dec

More News Resources


MedNotes
Latest FDA Drug Alerts
November 17, 2008
Audience: Consumers, dermatologists, pharmacists, other healthcare professionals[Posted 11/17/2008] CSI USA Inc. and FDA informed...
November 12, 2008
Audience: Consumers, pediatricians, other healthcare professionals[Posted 11/12/2008] Johnson & Johnson, Merck Consumer...
November 12, 2008
Audience: Geriatricians, gynecologists, orthopedic surgeons, other healthcare professionals[Posted 11/12/2008] FDA issued an...
November 10, 2008
Audience: Pharmacists, other healthcare professionals, patients [Posted 11/10/2008] Ethex Corp and FDA notified healthcare...
More...
Latest Drug Information Updates

Apriso
Apriso (mesalamine) is a once-daily, locally-acting aminosalicylate indicated for the maintenance of remission of ulcerative colitis (UC) in adults.

LoSeasonique
LoSeasonique is a lower-dose, extended-cycle oral contraceptive indicated for the prevention of pregnancy.

Acanya
Acanya (benzoyl peroxide and clindamycin phosphate) is a topical antibacterial and antibiotic combination for the treatment of acne.

Toviaz
Toviaz (fesoterodine fumarate) is a competitive muscarinic receptor antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.

Vimpat
Vimpat (lacosamide) is an anti-convulsant drug for the treatment of partial onset seizures in adults with epilepsy.

Astepro
Astepro (azelastine) is a nasal antihistamine for the treatment of seasonal allergic rhinitis.

Rapaflo
Rapaflo (silodosin) is an alpha(1)- adrenoreceptor antagonist for the treatment of the signs and symptoms associated with benign prostatic hyperplasia (BPH), or enlarged prostate.

Cinryze
Cinryze is a C1-esterase inhibitor indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with Hereditary Angioedema (HAE).

Akten
Akten (lidocaine hydrochloride) Ophthalmic Gel is a topical, ocular anesthetic formulation for use in ocular procedures that require a topical anesthetic agent.

AdreView
AdreView is a diagnostic radiopharmaceutical agent indicated for use in the detection of rare neuroendocrine tumors in children and adults.

Sancuso
Sancuso (granisetron transdermal system) is an anti-emetic transdermal delivery system indicated for the control of nausea and vomiting in patients receiving moderately and/or highly nausea-inducing chemotherapy.

Nplate
Nplate (romiplostim) is a thrombopoietin mimetic peptibody for the treatment of thrombocytopenia in adult patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP).

Xenazine
Xenazine (tetrabenazine) is a selective and reversible centrally-acting dopamine depleting drug indicated for the treatment of chorea associated with Huntington's disease.

Cleviprex
Cleviprex is an intravenous, ultrashort-acting calcium channel blocker under development for the treatment of severely elevated blood pressure in the hospital setting when oral therapy is not feasible or desirable.

Stavzor
Stavzor is delayed-release valproic acid formulated in the EnteriCare enteric soft gelatin capsule delivery system designed to minimize GI adverse events. Stavzor is indicated for the treatment of manic episodes associated with bipolar disorder, adjunctive therapy in multiple seizure types (including epilepsy), and prophylaxis of migraine headaches.

More...